TY - JOUR
T1 - Outcome of pediatric patients with acute myeloid leukemia (AML) and -5/5q- abnormalities from five pediatric AML treatment protocols
T2 - A report from the Children's Oncology Group
AU - Johnston, Donna L.
AU - Alonzo, Todd A.
AU - Gerbing, Robert B.
AU - Hirsch, Betsy
AU - Heerema, Nyla A.
AU - Ravindranath, Yaddanapudi
AU - Woods, William G.
AU - Lange, Beverly J.
AU - Gamis, Alan S.
AU - Raimondi, Susana C.
PY - 2013/12
Y1 - 2013/12
N2 - Background: Abnormalities of chromosome 5q (-5/5q-) are associated with poor prognosis in adults with acute myeloid leukemia (AML). However, there are no large studies on outcomes of children with -5/5q- AML. To determine the disease correlates of this group, we retrospectively analyzed cytogenetic data from five studies of childhood AML. Procedure: Data from patients whose cytogenetic clones included -5/5q-, with the exception of those with acute promyelocytic leukemia or Down syndrome, were included. Results: Of the 2,240 patients with cytogenetic data available, 26 (1.2%) had -5 or 5q-. A significant number of these patients were age 11-21 (61.5%, P=0.031) and had M0 morphology compared with patients without -5/5q- (24.0% vs. 2.8%, P<0.001). Twenty-two of the 26 patients had a complete remission (CR) response to induction chemotherapy. The 5-year overall survival (OS) from the time of diagnosis for the -5/5q- patients was significantly lower than for patients without -5/5q- (27±17% vs. 50±2%, P=0.027). Similarly, from induction CR, patients with -5/5q- had significantly worse disease free survival, OS and relapse risk than those without this abnormality (27±19% vs. 46±2%, P=0.035, 32±20% vs. 57±2%, P=0.025, 68±21% vs. 45±2%, P=0.01, respectively). Conclusions: Pediatric patients with AML and -5/5q- had a very poor outcome. These findings support the need for new or novel therapies for these patients. Pediatr Blood Cancer 2013;60:2073-2078.
AB - Background: Abnormalities of chromosome 5q (-5/5q-) are associated with poor prognosis in adults with acute myeloid leukemia (AML). However, there are no large studies on outcomes of children with -5/5q- AML. To determine the disease correlates of this group, we retrospectively analyzed cytogenetic data from five studies of childhood AML. Procedure: Data from patients whose cytogenetic clones included -5/5q-, with the exception of those with acute promyelocytic leukemia or Down syndrome, were included. Results: Of the 2,240 patients with cytogenetic data available, 26 (1.2%) had -5 or 5q-. A significant number of these patients were age 11-21 (61.5%, P=0.031) and had M0 morphology compared with patients without -5/5q- (24.0% vs. 2.8%, P<0.001). Twenty-two of the 26 patients had a complete remission (CR) response to induction chemotherapy. The 5-year overall survival (OS) from the time of diagnosis for the -5/5q- patients was significantly lower than for patients without -5/5q- (27±17% vs. 50±2%, P=0.027). Similarly, from induction CR, patients with -5/5q- had significantly worse disease free survival, OS and relapse risk than those without this abnormality (27±19% vs. 46±2%, P=0.035, 32±20% vs. 57±2%, P=0.025, 68±21% vs. 45±2%, P=0.01, respectively). Conclusions: Pediatric patients with AML and -5/5q- had a very poor outcome. These findings support the need for new or novel therapies for these patients. Pediatr Blood Cancer 2013;60:2073-2078.
KW - -5/5q- abnormalities
KW - Acute myeloid leukemia
KW - Chromosome 5
KW - Outcome
KW - Pediatric AML
UR - https://www.scopus.com/pages/publications/84885727057
UR - https://www.scopus.com/pages/publications/84885727057#tab=citedBy
U2 - 10.1002/pbc.24573
DO - 10.1002/pbc.24573
M3 - Article
C2 - 24039149
AN - SCOPUS:84885727057
SN - 1545-5009
VL - 60
SP - 2073
EP - 2078
JO - Pediatric Blood and Cancer
JF - Pediatric Blood and Cancer
IS - 12
ER -
